Seeking Alpha

NPS Pharmaceuticals (NPSP 14.3%) pops today after it says the FDA has released the briefing...

NPS Pharmaceuticals (NPSP 14.3%) pops today after it says the FDA has released the briefing documents ahead of its October 16 Advisory Committee meeting for NPSP's experimental drug Gattex, which is being developed for the treatment of adults with short bowel syndrome. The overall comments appear to be positive, with no serious safety issues raised. The advisers also said access to the drug should not be restricted, nor will it require additional elements to assure it's safe use.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|